Categories

Novel Small Molecule Targeting Huntington’s Disease Is Ready for Clinical Trials

Since 2019 Bicoll GmbH has supported Galyan Bio Inc. in developing and optimizing an orally available small molecule for Huntington's Disease Target. Clinical trials are scheduled for 2022.

Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to identify new scaffold for first-in-class clinical candidates. The new treatments interfere in the protein quality control system and are subsequently also useful for healthy aging.
media@galyan.bio

Contacts /

For more information, please contact:
Rohit Shyam
Chief Business Officer